Glucagon Efficiency After High and Low Carbohydrate Diet
HiLoCarb
1 other identifier
interventional
10
1 country
1
Brief Summary
No studies have investigated if the dietary composition of carbohydrate influences the glycaemic effect of single and multiple boluses of subcutaneous low-dose glucagon. Further, the recommended diet composition to patients with type 1 diabetes has not been thoroughly validated. Many patients with type 1 diabetes practice low carbohydrate eating patterns due to the assumption that this diet can reduce fluctuations in plasma glucose. Before glucagon can be used as an add-on to intensive insulin treatment, these aspects need to be elucidated. The purpose of this study is to determine, whether diet composition of carbohydrate affects the glycogen stores in the liver and affects the glucose response of glucagon during hypoglycaemia. HYPOTHESIS: In patients with type 1 diabetes, the glucose response of a single bolus of low-dose glucagon is not associated with diet carbohydrate content. AIM: The aim is to investigate how one week of high- compared to low-carbohydrate diet influence the glycaemic response of low-dose glucagon in patients with insulin pump treated type 1 diabetes. The secondary aim is to investigate how two dietary intervention weeks differ in the incidence of hypoglycaemia, postprandial hyperglycaemia, and daily glucose excursions. DESIGN:A non-blinded two-way cross-over, randomized study will be conducted. After participants have given an informed consent, they will go through four steps: 1) screening visit 2) Run-in period, 3) first meal intervention for one week finalizing with one study visit and 4) second meal intervention for one week finalizing with another study visit.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Oct 2015
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2015
CompletedFirst Submitted
Initial submission to the registry
October 14, 2015
CompletedFirst Posted
Study publicly available on registry
October 19, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2016
CompletedAugust 16, 2016
October 1, 2015
5 months
October 14, 2015
August 15, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Incremental area under the glucose curve
0-240 minutes
Peak glucose value
within 240 minutes
Secondary Outcomes (11)
Glucagon concentration
0-240 min.
Insulin concentration
0-240 min.
Triglycerides concentration
0-240 min.
Katekolamine concentration
0-240 min.
Ketone bodies concentration
0-240 min.
- +6 more secondary outcomes
Study Arms (2)
High carbohydrate diet
PLACEBO COMPARATORhigh carbohydrate intake
Low carbohydrate diet
ACTIVE COMPARATORlow carbohydrate intake
Interventions
Eligibility Criteria
You may qualify if:
- Age 18 - 70 years
- T1D ≥ 3 year
- BMI 20-27 kg/m2
- CSII ≥ 1 year
- HbA1c \< 69 mmol/mol (8.5 %)
- C-peptide negative (\< 60 pmol/l)
- Hypoglycemia awareness (self-reported)
- Use of carbohydrate counting and the insulin pump bolus calculator for all meals
You may not qualify if:
- Allergy or intolerance to lactose or Glucagen®(Novo Nordisk, Bagsværd, DK)
- Impaired renal function (eGFR \< 60 ml/min/1.73m2)
- Liver disease with ALAT \> 2.5 times the upper limit of the reference interval
- Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
- Known or suspected alcohol or drug abuse
- Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
- Females who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.
- Inability to understand the patient information and to give informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hvidovre University Hospitallead
- Danish Diabetes Academycollaborator
Study Sites (1)
Hvidovre University Hospital
Hvidovre, 2650, Denmark
Related Publications (1)
Ranjan A, Schmidt S, Damm-Frydenberg C, Steineck I, Clausen TR, Holst JJ, Madsbad S, Norgaard K. Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study. Diabetes Care. 2017 Jan;40(1):132-135. doi: 10.2337/dc16-1472. Epub 2016 Oct 21.
PMID: 27797928DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Kirsten Nørgaard, MD, DMSc
Hvidovre University Hospital
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD student
Study Record Dates
First Submitted
October 14, 2015
First Posted
October 19, 2015
Study Start
October 1, 2015
Primary Completion
March 1, 2016
Study Completion
July 1, 2016
Last Updated
August 16, 2016
Record last verified: 2015-10